Next Phase Newsletter

A venture capital firm based in Canada provides equity capital to portfolio companies and is very flexible in the size of investments it makes, placing a high emphasis on innovation of potential portfolio companies. The firm is currently investing in Canadian companies only, with no set limit on the amount of funds or number of investments.

The firm is looking to invest primarily in innovative green technology as well as biotech therapeutics and medical technology, and is also open to looking at companies in diagnostics and healthcare IT. The firm will consider products of any stage of development, from pre-clinical to phase III as long as the company’s product displays high potential to positively impact the environment or healthcare. In addition, the firm is agnostic to indication and will look at anything that fits in the environment or healthcare sectors.

The firm has taken a board seat in its portfolio companies before, but this is not required by the firm. The companies do not need to have an experienced management team, as innovation is the most important factor that the firm expects from companies. The firm prefers to act as the lead investor, but is open to co-investing with other firms that share the firm’s interests.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate investment arm of an Asia-based pharma firm is focused on early stage therapeutic companies that are a strategic fit for its parent company. Typical equity investments range from $0.5-5 million. The firm is also open to other forms of partnerships such as collaborative research, licensing, and M&A. The firm is currently seeking opportunities from across the US with a focus in the Bay Area.

The firm is looking opportunistically across all therapeutic subsectors from small molecules to biologics, gene therapy and cell therapy. The firm is most interested in assets in pre-IND to Phase II stages. The firm is agnostic to disease indications.

The firm is looking for experienced management team with strong sector knowledge. The firm may request board representation on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private investment firm based in Beijing, China, is investing from its 300 million RMB (US$50 million) fund into early stage ventures in the life sciences and healthcare sector. Typical allocation size ranges from US$0.5-5 million. The firm can either lead or follow in a financing round. The firm is seeking opportunities from China and the US.

The firm works on a wide range of life science sectors including biopharmaceuticals, medical devices, diagnostics, life science R&D, and medical services. The firm is especially interested in clinical stage molecular diagnostic products, while it would also consider preclinical stage projects with a lesser interest. The firm is agnostic to disease indications.

The firm is looking for experienced management team with proven products. The firm can assist with registration and distribution in China by leveraging its network of pharma partners, CRO/CMO, academic centers, and distribution channels. The firm is interested in distribution rights in China and may request board representation on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture firm with offices in Canada and the USA is investing from its second fund. The firm makes equity investments in early-stage life science companies based in Canada and the USA, and prefers to lead or co-lead investments. Initial investments will typically be of about $5 million CAD, with capital reserved for potential follow-on investments of up to $15 million CAD total per opportunity. The firm is likely to make 12-15 investments over the fund’s lifetime, with a focus on Canada; the firm also invests in the USA.

The firm will make most of its allocations in the therapeutics sector, with the remainder invested in diagnostics, medical devices, and/or tools or healthcare IT. The firm prefers to invest in early-stage opportunities; in the therapeutics sector, investments may be made in companies with a lead product 12-18 months prior to IND. The fund is generally agnostic in terms of technological field and indication area.

The firm only invests in those therapeutic companies that have identified a lead product candidate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private investment firm with offices in New York City and in Asia is investing from a US$180 million fund into the healthcare sector. Typical equity investments range from US$5-10 million in businesses from Series A to pre-IPO and public traded companies. The firm is opening to leading or following a syndicated round. The firm is now seeking opportunities in North America.

The firm invests across therapeutics, medical devices, diagnostics, platform technologies, and healthcare IT and is looking for companies that are top 3 in their niche sector. Within therapeutics, the firm prefer clinical stage projects. The firm is opportunistic in terms of disease areas including orphan indications. Within device and diagnostics, the firm prefers post-prototype products with clinical validation.

The firm may request board representation or board observership on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A major firm in the drug delivery device sector is interested in entering into joint ventures and strategic partnerships. These deals are typically accompanied by a minority investment of up to $10M. The firm seeks to be a value-added investor providing their expertise and capabilities in design and manufacturing as well as the resources of a large company while allowing the entrepreneur to drive the development of the technology. The group is also interested in outright acquisitions. The firm reserves a pool of capital from the balance sheet for these strategic investments.

The firm’s expertise lies in drug delivery devices, but has capabilities and is highly interested in all areas of medical technology/devices, biosensors and wearables, B2B or B2C healthcare IT applications including data analytics and cloud computing as well as robotics and AI as it applies to surgery prosthetics, rehabilitation and drug discovery. The firm has a particular interest in the diabetes space and has done work in this area in the past.

The firm is open to working with all entrepreneurs and is open to companies on a global basis. The firm does look for a board seat along with an investment, but strives to not be restrictive in any way and let the management team run the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The California-based life science venture investment arm of a leading global private investment firm invests across development stages, from early to late stages. The firm’s investment size is highly variable depending on the stage of the company, ranging from $1M to $25M in equity. The firm has a global mandate and is actively seeking new investment opportunities.

The firm seeks compelling investment opportunities in drug discovery and development platforms developing novel therapeutics, and medical devices. For therapeutics, the firm seeks small molecules and biologics and is open to all indications including orphan indications. The firm will consider products in all phases of clinical trials, from pre-clinical to phase III, and also commercial stage therapeutics. The firm is open to both PMA and 510K devices, as long as the device is already being sold at a commercial stage. The firm is also interested in services such as CROs and CMOs as well as tools of genomics and proteomics.

The firm invests for the long term, and is heavily involved in, and committed to, the growth and success of their portfolio companies. The firm, therefore, generally take a board seat/observer rights. The firm only invests in private companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com